Music |
Video |
Movies |
Chart |
Show |
Batch-to-batch PK variability of orally inhaled drug products (36of39) Complex Generics 2018 (U.S. Food and Drug Administration) View | |
Common BE Deficiencies for Orally Inhaled Drug Products in ANDAs (33of39) Complex Generics 2018 (U.S. Food and Drug Administration) View | |
BE for Bridging Studies with Orally Inhaled/Nasal Drugs (26of35) Complex Generics – Sep. 25-26, 2019 (U.S. Food and Drug Administration) View | |
The Potential of PK BE Studies in Detecting Regional Deposition with Orally Inhaled Drugs (U.S. Food and Drug Administration) View | |
Iron Colloid Drug Products: Characterization and Impurity (13of39) Complex Generics 2018 (U.S. Food and Drug Administration) View | |
Pre-ANDA Meeting Requests for Orally Inhaled/Nasal Drugs(24of35) Complex Generics – Sep. 25-26, 2019 (U.S. Food and Drug Administration) View | |
() View | |
() View | |
() View | |
() View |